[{"id":"a0b2e315-c24b-40d2-841a-430e9d381808","acronym":"BEAUTY","url":"https://clinicaltrials.gov/study/NCT02022202","created_at":"2021-01-18T09:15:13.266Z","updated_at":"2024-07-02T16:35:58.080Z","phase":"","brief_title":"Breast Cancer Genome Guided Therapy Study (BEAUTY)","source_id_and_acronym":"NCT02022202 - BEAUTY","lead_sponsor":"Mayo Clinic","biomarkers":" EGFR • HER-2 • KRAS • BRAF • PTEN • PI3K","pipe":" | ","alterations":" HER-2 positive • KRAS mutation • EGFR mutation • BRAF mutation • HER-2 amplification • HER-2 negative • PTEN mutation • KIT mutation • EGFR mutation + PTEN mutation","tags":["EGFR • HER-2 • KRAS • BRAF • PTEN • PI3K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • KRAS mutation • EGFR mutation • BRAF mutation • HER-2 amplification • HER-2 negative • PTEN mutation • KIT mutation • EGFR mutation + PTEN mutation"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 02/01/2013","start_date":" 02/01/2013","primary_txt":" Primary completion: 05/01/2014","primary_completion_date":" 05/01/2014","study_txt":" Completion: 12/14/2032","study_completion_date":" 12/14/2032","last_update_posted":"2023-01-06"},{"id":"4089d77e-fd91-4665-b6b6-7746742e0a38","acronym":"","url":"https://clinicaltrials.gov/study/NCT03750890","created_at":"2021-01-18T18:23:27.032Z","updated_at":"2024-07-02T16:37:01.335Z","phase":"","brief_title":"Visual Study of Molecular Genotype in Glioma Evolution","source_id_and_acronym":"NCT03750890","lead_sponsor":"Tongji Hospital","biomarkers":" EGFR • TP53 • PTEN • MGMT • TERT • ATRX","pipe":" | ","alterations":" TP53 mutation • EGFR mutation • EGFR amplification • PTEN mutation • ATRX mutation • TERT mutation • EGFR mutation + PTEN mutation","tags":["EGFR • TP53 • PTEN • MGMT • TERT • ATRX"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • EGFR mutation • EGFR amplification • PTEN mutation • ATRX mutation • TERT mutation • EGFR mutation + PTEN mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 1000","initiation":"Initiation: 01/01/2019","start_date":" 01/01/2019","primary_txt":" Primary completion: 12/31/2021","primary_completion_date":" 12/31/2021","study_txt":" Completion: 12/31/2022","study_completion_date":" 12/31/2022","last_update_posted":"2019-03-26"},{"id":"9f765fbc-04a0-4fbf-bad5-f946e6f9d268","acronym":"","url":"https://clinicaltrials.gov/study/NCT02696525","created_at":"2021-01-18T13:09:46.104Z","updated_at":"2024-07-02T16:37:10.627Z","phase":"","brief_title":"Circulating Tumor DNA Detection in Surveillance of Surgical Lung Cancer Patients","source_id_and_acronym":"NCT02696525","lead_sponsor":"Peking University People's Hospital","biomarkers":" EGFR • HER-2 • KRAS • BRAF • PIK3CA • PTEN • RAS","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • BRAF mutation • PIK3CA mutation • HER-2 mutation • PTEN mutation • EGFR mutation + PTEN mutation","tags":["EGFR • HER-2 • KRAS • BRAF • PIK3CA • PTEN • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • BRAF mutation • PIK3CA mutation • HER-2 mutation • PTEN mutation • EGFR mutation + PTEN mutation"],"overall_status":"Unknown status","enrollment":" Enrollment 145","initiation":"Initiation: 12/01/2018","start_date":" 12/01/2018","primary_txt":" Primary completion: 12/01/2021","primary_completion_date":" 12/01/2021","study_txt":" Completion: 12/01/2021","study_completion_date":" 12/01/2021","last_update_posted":"2018-05-21"}]